An Observational study analyzing humoral and cellular immune response after a third dose of SARS-CoV-2 vaccine in patients with rheumatoid arthritis
Latest Information Update: 04 Oct 2022
At a glance
- Drugs AZD 1222 (Primary) ; Tozinameran (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Pharmacodynamics
- 01 Oct 2022 Results assessing the immune response after a third dose of SARS-CoV-2 vaccine in patients with rheumatoid arthritis with undetectable antibody titers after the primary regimen of 2 doses, published in The Journal of Rheumatology
- 27 Jun 2022 New trial record
- 04 Jun 2022 Results presented at the 23rd Annual Congress of the European League Against Rheumatism